The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome
Information source: Gachon University Gil Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Eisenmenger's Syndrome
Phase: N/A
Status: Completed
Sponsored by: Gachon University Gil Medical Center
Summary
Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the
evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted
therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess
the effects of inhaled iloprost on patients with Eisenmenger's syndrome.
Clinical Details
Official title: Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome
Study design: Observational Model: Case-Only, Time Perspective: Retrospective
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization
Exclusion Criteria:
Locations and Contacts
Additional Information
Starting date: September 2007
Last updated: January 25, 2011
|